Department of Orthopedics, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, China.
J Orthop Surg Res. 2021 Mar 3;16(1):171. doi: 10.1186/s13018-021-02321-9.
When multicystic vesicles (precursors of exosomes) are formed in cells, there are two results. One is decomposition by lysosomes, and the other is the generation of exosomes that are transported out through the transmembrane. On the other hand, M2 macrophages promote the formation of local vascularization and provide necessary support for the repair of bone defects. To provide a new idea for the treatment of bone defects, the purpose of our study was to investigate the effect of WKYMVm (Trp-Lys-Tyr-Met-Val-D-Met-NH2) peptide on the secretion of exosomes from murine bone marrow-derived MSCs (mBMSCs) and the effect of exosomes on the polarization of M2 macrophages.
The WKYMVm peptide was used to activate the formyl peptide receptor 2 (FPR2) pathway in mBMSCs. First, we used Cell Counting Kit-8 (CCK-8) to detect the cytotoxic effect of WKYMVm peptide on mBMSCs. Second, we used western blotting (WB) and quantitative real-time polymerase chain reaction (qRT-PCR) to detect the expression of interferon stimulated gene 15 (ISG15) and transcription factor EB (TFEB) in mBMSCs. Then, we detected lysosomal activity using a lysozyme activity assay kit. Third, we used an exosome extraction kit and western blotting to detect the content of exosomes secreted by mBMSCs. Fourth, we used immunofluorescence and western blotting to count the number of polarized M2 macrophages. Finally, we used an inhibitor to block miRNA-146 in exosomes secreted by mBMSCs and counted the number of polarized M2 macrophages.
We first found that the WKYMVm peptide had no toxic effect on mBMSCs at a concentration of 1 μmol/L. Second, we found that when the FPR2 pathway was activated by the WKYMVm peptide in mBMSCs, ISG15 and TFEB expression was decreased, leading to increased secretion of exosomes. We also found that lysosomal activity was decreased when the FPR2 pathway was activated by the WKYMVm peptide in mBMSCs. Third, we demonstrated that exosomes secreted by mBMSCs promote the polarization of M2 macrophages. Moreover, all these effects can be blocked by the WRWWWW (WRW4, H-Trp-Arg-Trp-Trp-Trp-Trp-OH) peptide, an inhibitor of the FPR2 pathway. Finally, we confirmed the effect of miRNA-146 in exosomes secreted by mBMSCs on promoting the polarization of M2 macrophages.
Our findings demonstrated the potential value of the WKYMVm peptide in promoting the secretion of exosomes by mBMSCs and eventually leading to M2 macrophage polarization. We believe that our study could provide a research basis for the clinical treatment of bone defects.
当细胞中形成多囊泡体(外泌体的前体)时,会有两种结果。一种是被溶酶体分解,另一种是通过跨膜生成被运出的外泌体。另一方面,M2 巨噬细胞促进局部血管生成,并为骨缺损的修复提供必要的支持。为了为骨缺损的治疗提供新的思路,我们的研究目的是探讨 WKYMVm(Trp-Lys-Tyr-Met-Val-D-Met-NH2)肽对小鼠骨髓来源间充质干细胞(mBMSCs)分泌外泌体的影响,以及外泌体对 M2 巨噬细胞极化的影响。
WKYMVm 肽激活 mBMSCs 中的趋化因子受体 2(FPR2)通路。首先,我们使用细胞计数试剂盒(CCK-8)检测 WKYMVm 肽对 mBMSCs 的细胞毒性作用。其次,我们使用蛋白质印迹(WB)和实时定量聚合酶链反应(qRT-PCR)检测 mBMSCs 中干扰素刺激基因 15(ISG15)和转录因子 EB(TFEB)的表达。然后,我们使用溶酶体活性测定试剂盒检测溶酶体活性。第三,我们使用外泌体提取试剂盒和蛋白质印迹检测 mBMSCs 分泌的外泌体含量。第四,我们使用免疫荧光和蛋白质印迹计数极化 M2 巨噬细胞的数量。最后,我们使用抑制剂阻断 mBMSCs 分泌的外泌体中的 miRNA-146,并计数极化 M2 巨噬细胞的数量。
我们首先发现,当 WKYMVm 肽的浓度为 1μmol/L 时,对 mBMSCs 没有毒性作用。其次,我们发现当 WKYMVm 肽激活 mBMSCs 中的 FPR2 通路时,ISG15 和 TFEB 的表达减少,导致外泌体分泌增加。我们还发现,当 WKYMVm 肽激活 mBMSCs 中的 FPR2 通路时,溶酶体活性降低。第三,我们证明了 mBMSCs 分泌的外泌体促进 M2 巨噬细胞的极化。此外,所有这些作用都可以被 FPR2 通路的抑制剂 WRWWWW(WRW4,H-Trp-Arg-Trp-Trp-Trp-Trp-OH)肽阻断。最后,我们证实了 mBMSCs 分泌的外泌体中的 miRNA-146 对促进 M2 巨噬细胞极化的作用。
我们的研究结果表明,WKYMVm 肽在促进 mBMSCs 分泌外泌体并最终导致 M2 巨噬细胞极化方面具有潜在价值。我们相信,我们的研究可以为骨缺损的临床治疗提供研究基础。